BDSI - Have you looked at the company? Market caps only $78 million. They plan to expand the indications for Bema fentanyl if it gets approval.
"9:37AM BioDelivery Services secures U.S. commercial partnership for BEMA fentanyl with Meda AB (BDSI) 4.40 +0.40 : Co announces it has entered into an exclusive and perpetual license and related supply agreement with Meda for the U.S., Canadian and Mexican commercialization rights to BDSI's flagship BEMA Fentanyl product for the treatment of "breakthrough" cancer pain. Under this agreement, Meda will be responsible for the marketing and distribution of BEMA Fentanyl in the U.S., whose launch is anticipated in late 2008. In addition, Meda will be responsible for the management of the post-NDA approval clinical development program. Financial Aspects of the Partnership: 1st milestone: $30 mln upon closing which is contingent upon antitrust approval by the Federal Trade Commission, which typically occurs within 30 days of filing. -- 2nd milestone: $30 mln upon receipt of FDA approval, which is anticipated in late 2008. Royalty: BDSI to receive a significant double digit royalty on net sales. Guaranteed minimum annual royalties, based on low sales, exist during the first 7 years. -- Sales milestones: A total of $30 mln payable at: -- $10 mln when annualized sales exceeds $75 mln-- $10 mln when annualized sales exceeds $125 mln -- $10 mln when annualized sales exceeds $175 mln-- A gross margin above 70% is secured for Meda."
AI
